SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRANCHINI, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.368
EU - Europa 7.761
AS - Asia 6.296
SA - Sud America 884
Continente sconosciuto - Info sul continente non disponibili 407
AF - Africa 174
OC - Oceania 12
Totale 26.902
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.004
FI - Finlandia 3.937
SG - Singapore 2.336
IT - Italia 1.619
CN - Cina 1.482
VN - Vietnam 734
BR - Brasile 669
DE - Germania 518
HK - Hong Kong 480
PL - Polonia 313
GB - Regno Unito 297
UA - Ucraina 240
BD - Bangladesh 228
TR - Turchia 210
FR - Francia 206
CA - Canada 192
JP - Giappone 192
IN - India 160
ID - Indonesia 141
SE - Svezia 135
RU - Federazione Russa 132
MX - Messico 110
NL - Olanda 79
AR - Argentina 76
ZA - Sudafrica 69
IQ - Iraq 51
ES - Italia 46
PK - Pakistan 39
EC - Ecuador 35
BE - Belgio 34
CZ - Repubblica Ceca 29
CO - Colombia 28
MY - Malesia 28
VE - Venezuela 27
CL - Cile 24
MA - Marocco 24
NO - Norvegia 24
LT - Lituania 21
SA - Arabia Saudita 21
AT - Austria 20
DK - Danimarca 19
RO - Romania 18
IR - Iran 17
PH - Filippine 17
UZ - Uzbekistan 17
AE - Emirati Arabi Uniti 16
IE - Irlanda 16
KE - Kenya 16
TW - Taiwan 16
JM - Giamaica 14
JO - Giordania 14
DZ - Algeria 13
CR - Costa Rica 12
ET - Etiopia 12
NP - Nepal 12
CH - Svizzera 11
KR - Corea 11
AU - Australia 10
EG - Egitto 10
EU - Europa 10
AZ - Azerbaigian 9
IL - Israele 9
TH - Thailandia 8
TT - Trinidad e Tobago 8
AL - Albania 7
NG - Nigeria 7
PT - Portogallo 7
PY - Paraguay 7
TN - Tunisia 7
UY - Uruguay 7
DO - Repubblica Dominicana 6
GE - Georgia 6
PE - Perù 6
GR - Grecia 5
GT - Guatemala 5
HR - Croazia 5
KZ - Kazakistan 5
LB - Libano 5
BH - Bahrain 4
BO - Bolivia 4
HN - Honduras 4
KG - Kirghizistan 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
KW - Kuwait 3
PS - Palestinian Territory 3
SV - El Salvador 3
AF - Afghanistan, Repubblica islamica di 2
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
BY - Bielorussia 2
EE - Estonia 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
MN - Mongolia 2
Totale 26.469
Salva come PNG Salva come JPEG
Città #
Helsinki 3.841
Singapore 1.418
Ashburn 1.155
Dallas 1.063
San Jose 974
Chandler 570
Santa Clara 555
Fairfield 506
Beijing 465
Hong Kong 451
Council Bluffs 444
Woodbridge 441
Ferrara 366
New York 327
Warsaw 305
Houston 299
Ann Arbor 278
Ho Chi Minh City 248
Los Angeles 242
Seattle 225
Wilmington 222
Jacksonville 219
Tokyo 181
Cambridge 173
Hanoi 169
Munich 161
Milan 148
Izmir 121
Princeton 120
Jakarta 106
Lauterbourg 104
Nanjing 101
Shanghai 99
Dearborn 88
São Paulo 88
Rome 74
Boardman 69
Toronto 69
Orem 66
The Dalles 63
Bremen 62
Mexico City 62
London 61
Denver 56
Montreal 56
Phoenix 52
Brooklyn 48
Atlanta 47
Chicago 47
San Diego 47
Turku 43
Redwood City 41
Chennai 39
Frankfurt am Main 39
Johannesburg 39
Bologna 38
Buffalo 37
Florence 36
Nanchang 36
Falls Church 35
San Francisco 35
Shenyang 34
Poplar 33
Guangzhou 31
Tianjin 31
Da Nang 29
Haiphong 29
Manchester 29
Brussels 26
Falkenstein 26
Moscow 26
Hefei 25
Amsterdam 23
Baghdad 23
Dong Ket 23
Boston 22
Rio de Janeiro 22
Hebei 21
Jiaxing 21
Nuremberg 21
Auburn Hills 20
San Mateo 20
Changsha 19
Mumbai 19
Naples 19
Ankara 18
Charlotte 18
Jinan 18
Paris 18
Stockholm 18
Washington 18
Biên Hòa 17
Brno 17
Columbus 17
Oslo 17
Brasília 16
Hangzhou 16
Kunming 16
Tashkent 16
Hải Dương 15
Totale 18.417
Salva come PNG Salva come JPEG
Nome #
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 2.878
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 2.061
La sanificazione delle degenze ospedaliere: nuove strategie per la riduzione delle infezioni correlate all’assistenza sanitaria 476
La sanificazione delle degenze ospedaliere: nuove strategie a supporto della riduzione delle infezioni correlate all’assistenza sanitaria 419
Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation 364
Il sistema di sanificazione PCHS Probiotic Cleaning Hygien System: risultati delle indagini sperimentali in vitro e in campo 362
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 318
The carboxyl-terminal region of coagulation factors: role in biosynthesis and function of FVII and FX 316
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 314
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 297
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 297
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties 284
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 281
Hard surface biocontrol in hospitals using microbial-based cleaning products 275
PCHS (Probiotic Hygiene Cleaning System) Protocol: reduction of hospital environmental impact with a new and innovative technology for cleaning in Ferrara University Hospital 274
I probiotici: aspetti generali e valutazioni sulla sicurezza d’impiego 261
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 255
Chronic sleep deprivation markedly reduces coagulation factor VII expression 249
Reduction of the microbial load on hospital surfaces through probiotic-based cleaning procedures: a new strategy to control nosocomial infections 249
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 247
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 243
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 242
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 226
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 221
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 218
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 218
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 217
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 215
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 213
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 209
Characterization of PAR-mediated signaling induced by activated coagulation factor X mutants 203
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 203
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 200
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 200
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 199
Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 195
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 191
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction 189
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 189
An integrated multi-tool analysis contributes elements to interpreting unclassified factor IX missense variants associated with haemophilia B 188
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 188
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 186
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 186
Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype 184
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 183
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 180
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 180
The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA 179
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 176
Improved intracellular processing of protein variants as a personalized therapeutic approach for Haemophilia 175
F9 genotype and PK hemophilia B international study (GEPKHIS) 175
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 174
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 173
An engineered factor X variant as a novel by-passing agent for hemophilia 171
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 171
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 167
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 167
Comparative Analysis Of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B- domain Favours Readthrough- mediated Protein Output 165
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough 165
RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations 164
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 163
Hemostasis gene expression of the internal jugular and saphenous veins 163
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 162
Molecular insights into determinants of translational readthrough and implications for nonsense suppression approaches 161
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 159
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 158
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 153
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 152
Exploring spontaneous readthrough over recurrent F8 nonsense mutations: potential correlation with inhibitor risk? 151
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 150
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 149
A recoded view on the F9 p.Cys178Ter pathogenic mechanism 149
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 148
Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies 145
Academic Editor per la rivista PLoS One 145
Identification of novel mechanisms underlying functional response to drug-induced readthrough of haemophilia B nonsense mutations 144
The FVII R402X nonsense mutation, associated with an asymptomatic phenotype, is responsible for small amounts of circulating protein with improved coagulant activity 140
Translation termination codons in protein synthesis and disease 139
“Compensatory” aberrant splicing supports residual expression levels in severe coagulation factor VII deficiency 139
MOLECULAR MECHANISMS AND THERAPEUTIC APROACHES FOR RESTORATION OF mRNA TRANSCRIPTION, MATURATION AND TRANSLATION IN INHERITED COAGULATION FACTOR DEFICIENCIES 139
Effects of Partial Chronic Sleep Deprivation on the Mouse Blood Coagulation Cascade. 139
A new type 1 von Willebrand Disease (VWD) characterized by increased clearance of von Willebrand Factor (VWF) due to the heterozygous p.P1127S mutation: clinical phenotype and pathogenic mechanisms 137
A factor X variant with engineered activation peptide as innovative by-passing agent for haemophilia 136
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 135
Engineered transcription factors (TALE-TF) as potential therapeutic strategy for coagulation factor deficiencies caused by promoter mutations 131
Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations 129
Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity 128
Next generation factor VIIa with enhanced half-life 128
The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones 126
Genotype and PK Hemophilia B International Study (GePKHIS) - A progress Report 124
RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations 122
Naturally occurring truncated proteins: decreased protein secretion and increased activity result in asymptomatic coagulation factor deficiency 115
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 113
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 111
Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B 107
Engineered suppressor tRNAs as a novel correction approach for recurrent hemophilia A-causing nonsense mutations 106
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 106
Associate Editor per la rivista Frontiers in Pediatrics - sezione Genetic Disorders 103
Mapping of inhibitory antibodies directed to the carboxy-terminus of FVIIa in severe FVII deficiency with elongated C-terminal variant (p.A354V-p.P464Hfs†) 102
Coagulation factor VII variants resistant to inhibitory antibodies 101
Totale 23.573
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.969
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 726
Totale 107.695
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022872 0 0 37 36 82 72 49 48 35 84 74 355
2022/20231.242 132 144 50 174 179 158 77 79 135 11 58 45
2023/2024856 63 67 44 32 54 156 41 62 29 33 44 231
2024/20253.349 102 78 302 108 394 371 78 90 523 383 507 413
2025/202614.086 944 550 1.259 1.308 1.385 652 1.158 474 4.600 963 490 303
2026/20271.328 418 526 384 0 0 0 0 0 0 0 0 0
Totale 26.902